Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Rastogi, 2020
RCTVitamin DplaceboCOVID-19 mild to moderateNA
16/24 suggested
  • suggested 5.3-fold increase in PCR-negative conversion (PE)

COVID-19 severe or critically meta-analysis

Murai, 2020
RCTVitamin DplaceboCOVID-19 severe or criticallysome concern
120/120 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).